Building on the first FDA‐approved Menin inhibitor (revumenib), this review delineates emerging PROTAC‐ and WDR5‐targeted approaches, machine‐learning–predicted biomarkers, and nascent immunotherapies, offering a comprehensive roadmap for next‐generation, precision‐guided management of KMT2A‐rearranged AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.